GlassScriptPhysician profile
John R Eplee
NPI 1114948635
$767.27
in general payments reported to CMS, 2019-2025
22 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.08 · 2020: $14.74 · 2021: $206 · 2022: $144 · 2023: $89.86 · 2024: $86.89 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.38 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $90.44 | 2021-2022 | |
| Glaxosmithkline, LLC. | $63.68 | 2021-2024 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.88 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $54.73 | 2022-2023 | Mounjaro |
| Pfizer INC. | $45.48 | 2019-2025 | |
| Novo Nordisk INC | $42.28 | 2022 | |
| Genentech USA, INC. | $38.71 | 2019-2021 | |
| Astellas Pharma US INC | $36.22 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $30.54 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.52 | 2022-2025 | Caplyta |
| Abbvie INC. | $23.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.88 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $18.30 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.77 | 2025 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novavax INC | $16.32 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Biohaven Pharmaceuticals, INC. | $16.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.39 | 2025 | |
| Electromed, INC. | $13.74 | 2024 | Smartvest |
| Biohaven Pharmaceutical Holding Company LTD. | $12.07 | 2022 | |
| Allergan, INC. | $11.87 | 2019 | |
| Cequr Corporation | $11.33 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eplee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.